Transcenta Holding Limited (HKG:6628)

Market Cap	644.24M +28.0%
Revenue (ttm)	8.27M -34.0%
Net Income	-226.71M
EPS	-0.55
Shares Out	426.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,464,000
Open	1.670
Previous Close	1.680
Day's Range	1.500 - 1.670
52-Week Range	1.370 - 5.800
Beta	-0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 3, 2026

About Transcenta Holding

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST808, a humanized antibody regulating B/plasma cell; TST005, a PD-L1/TGF-β b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 171
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6628

Financial Performance

In 2025, Transcenta Holding's revenue was 7.44 million, a decrease of -33.98% compared to the previous year's 11.26 million. Losses were -203.73 million, -29.82% less than in 2024.

Financial numbers in CNY